Aikido Pharma Inc. SPEX Cash Flow

Aikido pharma inc. (SPEX)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities
Net loss
-8,333	973	-3,363	-644	-1,149	5,502	-1,891	-398	-1,486	-986	459	-1,860	-919	-3,903	-446	-2,078	-49	-4,345	-2,726	-40,308	-4,086	-5,857	-5,144	-11,568	-7,963	-4,181	-9,280	-807	-3,697	-1,910	-707	-404	-834	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-913	-1,013	-235
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of patent portfolio
-	-	-	-	-	378	346	343	338	346	346	343	338	537	536	531	531	-	-	-	2,422	2,477	2,476	2,450	2,428	133	134	0	0	-	-	-	-	-	-	-	-
Change in fair value of investment
-5,071	4,171	-2,435	145	-475	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash registration rights penalty
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-46	700	0	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of warrant liabilities
-	1	7	127	-53	180	95	277	188	139	1,067	-1,204	-122	202	1,024	-511	1,542	-	-	-	0	95	0	-7	-40	-	-	-	-	-	-	-	-	-	-	-	-
Research and development-acquired license, expensed
1,011	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on settlement of obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,690	0	0	845
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16	18	15	13	16	17	19
Fair value adjustment of warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58	-342	-339	-	-	-	-
Recovery of bad debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13
Stock-based compensation
-	0	214	109	6	6	28	98	188	10	2	7	4	209	54	168	131	148	89	47	87	722	1,566	6,992	3,396	-	-	-	4	15	20	16	2	-	-	-	-
Fair value adjustments for warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37	-139	2,786	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	0	21	16	1	1	2	-1	1	2	0	1	0	-	-	-	-	-	-	-	-	0	2	6	16	-	-	-	-	-	-	-	-
Realized loss on marketable securities
-44	-42	-32	-25	-73	-39	-86	-176	-99	-25	-174	-36	-93	-95	57	9	-66	-	-	-	-53	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss (gain) on marketable securities
-835	13	-6	-10	148	-103	3	41	-58	-22	125	65	72	-181	-91	17	12	-	-	-	57	-54	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Other receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	1	4	-1	-	-	-	-	524	25	56	-344
Prepaid expenses and other assets
-16	129	-54	-64	-18	112	-70	-82	78	108	-53	-50	10	76	-40	-193	-38	310	-53	2	-36	-127	19	20	44	-74	33	13	14	-80	31	44	241	694	-184	-150	-69
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36	94	-27	-	-	-	-
Accounts payable and accrued expenses
102	-189	25	110	-10	62	-138	40	110	8	-55	-72	52	59	-196	-95	-29	-57	-70	-163	-54	583	-626	432	69	13	93	-2	-262	344	133	-114	-170	125	74	-41	-526
Accrued salaries and benefits
-244	88	-11	-43	-84	154	-14	-33	-70	426	187	-257	-107	-88	460	-37	-534	430	-50	-369	305	290	-2	-36	-156	-52	0	0	0	-	-	-	-	-	-	-	-
Payable to DatChat
-50	-100	0	77	130	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-284	-314	-311	-307	-315	-314	4,197	-71	-	-	-	0	-	-	-	-	-	-	-	-	-8	12	1	-8	-8	-8	-8	-7
Accrued lease liabilities
-	-	-	-	-	0	0	0	-48	-46	-46	-47	-40	-47	-43	-45	-45	-	-	-	-43	580	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of patent portfolio
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-1,448	-788	-615	-718	-896	-440	-539	-674	-1,076	-725	-731	-971	-845	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-28	-74
Deferred compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-305
Net cash used in activities of continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,631	-1,659	-922	-1,140	-1,316	-547	-680	-1,103	-	-	-980	969
Net cash provided by (used in) activities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	-2	-5	89	-184	0	81	-63	-	-	-	-
Net cash (used in) provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,320	-1,516	-906	-1,222	-1,155	-1,337	-4,749	-1,482	-1,763	-1,522	-1,627	-1,661	-927	-1,051	-1,501	-547	-599	-1,166	-1,257	-547	-980	-1,573
Purchase of marketable securities
20,378	1,810	1,697	2,109	2,845	970	3,263	4,707	5,340	991	4,773	2,389	4,121	2,328	5,514	6,737	3,456	4,220	0	5	3,769	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of marketable securities
4,215	1,861	1,538	2,513	4,365	1,537	4,405	5,512	3,607	1,680	2,909	4,582	5,042	2,995	4,184	2,560	5,326	1,667	-29	2,071	4,412	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of investments at fair value
-	-350	0	350	200	-	-	-	-	0	0	675	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of research and development licenses
1,011	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
-	-	-	-	-	0	20	-9	25	-	-	-	-	1	0	1	2	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of accrued patent costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	0	0	-1,000	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by activities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-	-	-	-
Net cash (used in) provided by investing activities
-17,174	41	-159	54	1,320	348	470	789	-1,758	689	-1,864	1,518	921	-	-	-	1,868	-	-	-	643	4	-4	0	-1,000	-24	682	0	0	3	0	-0	-1	-	-	-	-
Cash flows from financing activities
Proceeds from issuance common stock, common warrants and prefunded warrants, net of offering cost
6,549	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-2	0	-2
Proceeds from issuance common stock, net of offering cost
5,095	-	-	-	-	0	0	0	2,700	0	2,095	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-94	1,150	1,489	0	-0	2,545
Proceeds from issuance of common stock and warrants in July Financing, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,874	0	-26	3,900	310	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
7,139	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	-	-	-	-
Net cash provided by financing activities
18,783	-	-	-	-	0	0	0	2,700	0	2,095	-24	0	-	-	-	-	-	-	-	-	0	-110	4,406	3,900	2,235	500	500	0	2,346	-1	-10	1,066	-	-	-	-
Issuance cost of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	-	-	-	-
Net cash (used in) provided byfinancing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,066	1,155	0	-0	2,545
Net increase in cash and cash equivalents
161	-222	-251	123	424	-92	-69	115	-134	-36	-500	523	76	-169	-89	-102	352	-15	70	-24	-694	-4,745	-1,596	2,643	1,378	584	-479	-427	-1,051	848	-548	-609	-102	-	-	-	-
Cash paid for interest and taxes
-	-	-	-	-	-	-	-	-	0	195	0	0	0	0	0	0	-	-	-	0	0	0	0	0	-	-	-	-	-	0	0	0	-	-	-	-
Cash paid for interest and taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Non-cash investing and financing activities
Offering cost included in accrued expenses
7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retirement of treasury stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	201	0	0	0	0	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2	0	1	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of Series C Convertible Preferred Stock in connection with exchange of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Issuance of Series C Convertible Preferred Stock in connection with exchange of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	5,696	-	-	-	-	-	-	-	-